| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| review article | Q7318358 |
| P356 | DOI | 10.1002/14651858.CD000222.PUB3 |
| P698 | PubMed publication ID | 25501301 |
| P50 | author | Deborah Ashby | Q20876093 |
| P2093 | author name string | Katharine Cheng | |
| Rosalind L Smyth | |||
| P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
| Liver disease in cystic fibrosis: an update | Q28662082 | ||
| Meta-analyses involving cross-over trials: methodological issues | Q29620304 | ||
| Ursodeoxycholic acid for cystic fibrosis-related liver disease. | Q33909429 | ||
| Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. | Q51604167 | ||
| The role of hepatobiliary scintigraphy in cystic fibrosis. | Q53992541 | ||
| Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study. | Q55062995 | ||
| Effect of a Medium Dose of Ursodeoxycholic Acid with or without Taurine Supplementation on the Nutritional Status of Patients with Cystic Fibrosis | Q60199019 | ||
| Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial | Q68019501 | ||
| Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis | Q71173367 | ||
| Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis | Q72999026 | ||
| Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up | Q73317238 | ||
| Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review | Q73468107 | ||
| Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood | Q84068608 | ||
| Liver disease in cystic fibrosis | Q86955883 | ||
| P921 | main subject | cystic fibrosis | Q178194 |
| liver disease | Q929737 | ||
| P577 | publication date | 2014-12-15 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Ursodeoxycholic acid for cystic fibrosis-related liver disease |
| Q44853838 | Case Report: Ursodeoxycholic acid treatment in Niemann-Pick disease type C; clinical experience in four cases. |
| Q91656776 | Cystic Fibrosis-Related Liver Diseases: New Paradigm for Treatment Based on Pathophysiology |
| Q33431380 | Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis |
| Q53098241 | Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. |
| Q57126201 | Ursodeoxycholic acid for cystic fibrosis-related liver disease |
Search more.